Anzeige
Mehr »
Login
Freitag, 26.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire
1.157 Leser
Artikel bewerten:
(2)

Coloplast A/S: Coloplast acquires SAS Lilial

Today Coloplast A/S acquires the French direct-to-consumer home delivery
company SAS Lilial (Lilial) for a cash consideration of EUR 35.5m equal to
approx. DKK 264m. 

Lilial is a privately owned, French direct-to consumer home delivery company
with nationwide distribution of primarily catheter and ostomy supplies founded
in 2003. Lilial provides patients with products from several different
manufacturers including Coloplast. The company has approx. 80 employees and is
expected to record sales of approx. EUR 33m or approx. DKK 246m for the
full-year 2017. 

The acquisition is a continuation of Coloplast's overall ambition to secure its
end users innovative products and services. Furthermore, the acquisition
strengthens Coloplast's position and offering in France, where Coloplast
expects to continue to work closely with healthcare professionals and channel
partners with the intent of improving overall end user outcomes. 

"The acquisition of SAS Lilial is part of our strategy of pursuing inorganic
opportunities to accelerate growth and to strengthen our service offerings. By
acquiring Lilial we further strengthen our position in France and ensure our
end users access to innovative products and services. Lilial is a great match
for Coloplast, and I am very happy to welcome Lilial to the Coloplast family,"
said Coloplast CEO Lars Rasmussen. 

The acquisition leads to a revised financial guidance for the financial year
2017/18: 

The organic revenue growth guidance of ~7% is unchanged. The growth in DKK of
5-6% based on spot rates as of 31 October 2017, is expected to be ~1%-points
higher. 

The EBIT margin guidance of 31-32% in constant exchange rates and about 31% in
DKK is unchanged. 

The transaction is expected to contribute to Coloplast's long-term growth
ambition. The long-term guidance for the LEAD 20 strategy period until fiscal
year-end 2019/20 of 7-9% organic growth p.a. and an EBIT margin of more than
30% in constant currencies is unchanged. 

For more information on Lilial please refer to www.lilial.fr

CONTACTS                                                
Lina Danstrup                                           
Senior Media Relations Manager, Corporate Communications
+45 49 11 26 07                                         
dklina@coloplast.com                                    
Ellen Bjurgert                                          
Director, Investor Relations                            
+45 49 11 33 76                                         
dkebj@coloplast.com

Attachment:
https://cns.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=657467
Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2017 GlobeNewswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.